知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

44 records (took 0.066 seconds)

    ANTIBODIES WHICH BIND SOLUBLE T-CELL RECEPTOR LIGANDS
    2.
    发明申请
    ANTIBODIES WHICH BIND SOLUBLE T-CELL RECEPTOR LIGANDS 审中-公开
    抗体可溶性T细胞受体配体

    公开(公告)号：US20140170168A1

    公开(公告)日：2014-06-19

    申请号：US13881414

    申请日：2011-10-26

    Applicant: Yoram Reiter ,  Rony Dahan ,  Arthur A. Vandenbark

    Inventor： Yoram Reiter ,  Rony Dahan ,  Arthur A. Vandenbark

    IPC: C07K16/28 ,  G01N33/564

    CPC classification number: C07K16/2809 ,  C07K16/2833 ,  G01N33/564

    Abstract: Provided are isolated high affinity entities which comprise an antigen binding domain which specifically binds a soluble T-cell receptor ligand comprising a two-domain beta1-alpha1 of a major histocompatibility complex (MHC) class II, wherein said antigen binding domain does not bind a complex comprising a four-domain alpha1-beta1/alpha2-beta2 MHC class II. Also provided are methods and kits using same for detecting and sequestering soluble two-domain T cell receptor ligands in a sample.

    Abstract translation: 提供了分离的高亲和力实体，其包含特异性结合可溶性T细胞受体配体的抗原结合结构域，所述可溶性T细胞受体配体包含II类主要组织相容性复合物（MHC）的双结构域β1-α1，其中所述抗原结合结构域不结合 复合物包含四结构域α1-β1/α2-β2MHC II类。 还提供了使用其在样品中检测和螯合可溶性双结构域T细胞受体配体的方法和试剂盒。

    ANTIBODIES WITH T-CELL RECEPTOR LIKE SPECIFICITY TOWARDS NATIVE COMPLEXES OF MHC CLASS II AND DIABETES-ASSOCIATED AUTOANTIGENIC PEPTIDES
    3.
    发明申请
    ANTIBODIES WITH T-CELL RECEPTOR LIKE SPECIFICITY TOWARDS NATIVE COMPLEXES OF MHC CLASS II AND DIABETES-ASSOCIATED AUTOANTIGENIC PEPTIDES 审中-公开
    具有T细胞受体特异性的抗体涉及MHC II类和与糖尿病相关的自身抗原肽的本体复合物

    公开(公告)号：US20130189284A1

    公开(公告)日：2013-07-25

    申请号：US13810248

    申请日：2011-07-14

    Applicant: Yoram Reiter ,  Rony Dahan

    Inventor： Yoram Reiter ,  Rony Dahan

    IPC: C07K14/705 ,  C07K14/62 ,  C12N9/16 ,  G01N33/68 ,  C12N9/88 ,  C07K16/28 ,  C07K14/47

    CPC classification number: C07K14/705 ,  C07K14/47 ,  C07K14/62 ,  C07K16/28 ,  C07K16/2833 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/55 ,  C07K2317/76 ,  C12N9/16 ,  C12N9/88 ,  G01N33/6854 ,  G01N33/6893

    Abstract: Provided are isolated complexes comprising a major histocompatibility complex (MHC) class II and a type I diabetes-associated autoantigenic peptide, the isolated complex having a structural conformation which enables isolation of a high affinity entity which comprises an antigen binding domain capable of specifically binding to a native conformation of a complex composed of the MHC class II and the type I diabetes-associated autoantigenic peptide; and isolated high affinity entities comprising an antigen binding domain capable of specifically binding the complex, wherein the isolated high affinity entity does not bind to the MHC class II in an absence of the diabetes-associated autoantigenic peptide, wherein the isolated high affinity entity does not bind to the diabetes-associated autoantigenic peptide in an absence of the MHC class II; and methods and kits using same for diagnostic and therapeutic purposes.

    Abstract translation: 提供了包含主要组织相容性复合体（MHC）II类和I型糖尿病相关的自身抗原肽的分离的复合物，所述分离的复合物具有能够分离高亲和力实体的结构构象，其包含能够特异性结合 由MHC II类和I型糖尿病相关的自身抗原肽组成的复合物的天然构象; 和分离的高亲和力实体，其包含能够特异性结合复合物的抗原结合结构域，其中所述分离的高亲和力实体在不存在与糖尿病相关的自身抗原肽的情况下不结合MHC II类，其中所述分离的高亲和力实体不 在没有MHC II类的情况下与糖尿病相关的自身抗原肽结合; 以及用于诊断和治疗目的的方法和试剂盒。

    MHC-PEPTIDE COMPLEX BINDING LIGANDS
    6.
    发明申请
    MHC-PEPTIDE COMPLEX BINDING LIGANDS 审中-公开
    MHC-肽复合结合配体

    公开(公告)号：US20100228007A1

    公开(公告)日：2010-09-09

    申请号：US12724486

    申请日：2010-03-16

    Applicant: Henricus Renerus Jacobus Mattheus HOOGENBOOM ,  Yoram Reiter

    Inventor： Henricus Renerus Jacobus Mattheus HOOGENBOOM ,  Yoram Reiter

    IPC: C07K16/00

    CPC classification number: C07K16/2896 ,  A61K2039/505 ,  C07K16/2833 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55

    Abstract: Disclosed are protein ligands comprising an immunoglobulin heavy chain variable (VH) domain and an immunoglobulin light chain variable (VL) domain, wherein the proteins bind a complex comprising an MHC and a peptide, do not substantially bind the MHC in the absence of the bound peptide, and do not substantially bind the peptide in the absence of the MHC, and the peptide is a peptide fragment of gp100, MUC1, TAX, or hTERT. Also disclosed are methods of using and identifying such ligands.

    Abstract translation: 公开了包含免疫球蛋白重链可变（VH）结构域和免疫球蛋白轻链可变（VL）结构域的蛋白质配体，其中所述蛋白质结合包含MHC和肽的复合物，在不存在结合的情况下基本上不结合MHC 肽，并且在不存在MHC的情况下基本上不结合肽，并且该肽是gp100，MUC1，TAX或hTERT的肽片段。 还公开了使用和鉴定这种配体的方法。

    SINGLE CHAIN CLASS I MAJOR HISTOCOMPATIBILITY COMPLEXES, CONSTRUCTS ENCODING SAME AND METHODS OF GENERATING SAME
    7.
    发明申请
    SINGLE CHAIN CLASS I MAJOR HISTOCOMPATIBILITY COMPLEXES, CONSTRUCTS ENCODING SAME AND METHODS OF GENERATING SAME 审中-公开
    单链类I主要组氨酸复合物，编码其的构建体及其生成方法

    公开(公告)号：US20090258393A1

    公开(公告)日：2009-10-15

    申请号：US12486794

    申请日：2009-06-18

    Applicant: Yoram REITER

    Inventor： Yoram REITER

    IPC: C12P21/00 ,  C12N1/21 ,  C07K16/00

    CPC classification number: C07K14/70539

    Abstract: Provided are methods of generating a functional mammalian single chain MHC class I complex in prokaryotic expression systems and a host cell transformed with expression construct(s) capable of expressing a functional human single chain MHC class I complex capable of presenting specific antigenic peptides restricted to specific CTL clones.

    Abstract translation: 提供的是在原核表达系统中产生功能性哺乳动物单链MHC I类复合物的方法和用能够表达功能性人单链MHC I类复合体的表达构建体转化的宿主细胞，其能够呈递限于特异性的特异性抗原肽 CTL克隆。

    MHC-peptide complex binding ligands
    9.
    发明申请
    MHC-peptide complex binding ligands 有权
    MHC-肽复合物结合配体

    公开(公告)号：US20070196369A1

    公开(公告)日：2007-08-23

    申请号：US11582416

    申请日：2006-10-18

    Applicant: Henricus Renerus Hoogenboom ,  Yoram Reiter

    Inventor： Henricus Renerus Hoogenboom ,  Yoram Reiter

    IPC: A61K39/395 ,  C07K16/28

    CPC classification number: C07K16/2896 ,  A61K2039/505 ,  C07K16/2833 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55

    Abstract: Disclosed are protein ligands comprising an immunoglobulin heavy chain variable (VH) domain and an immunoglobulin light chain variable (VL) domain, wherein the proteins bind a complex comprising an MHC and a peptide, do not substantially bind the MHC in the absence of the bound peptide, and do not substantially bind the peptide in the absence of the MHC, and the peptide is a peptide fragment of gp100, MUC1, TAX, or hTERT. Also disclosed are methods of using and identifying such ligands.

    Abstract translation: 公开了包含免疫球蛋白重链可变（VH）结构域和免疫球蛋白轻链可变（VL）结构域的蛋白质配体，其中所述蛋白质结合包含MHC和肽的复合物，在不存在结合的情况下基本上不结合MHC 肽，并且在不存在MHC的情况下基本上不结合肽，并且该肽是gp100，MUC1，TAX或hTERT的肽片段。 还公开了使用和鉴定这种配体的方法。

    Method of predicting responsiveness to autologous adoptive cell transfer therapy
    10.
    发明授权
    Method of predicting responsiveness to autologous adoptive cell transfer therapy 有权
    预测自体过继细胞转移治疗反应的方法

    公开(公告)号：US08541185B2

    公开(公告)日：2013-09-24

    申请号：US12679696

    申请日：2008-09-15

    Applicant: Kfir Oved ,  Eran Eden ,  Martin Akerman ,  Roy Noy ,  Michal Besser ,  Yoram Reiter

    Inventor： Kfir Oved ,  Eran Eden ,  Martin Akerman ,  Roy Noy ,  Michal Besser ,  Yoram Reiter

    IPC: G01N33/574 ,  C12Q1/02 ,  C12N5/07

    CPC classification number: G01N33/57484 ,  G01N33/505 ,  G01N2800/52

    Abstract: A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8+CD28−CD152− signature in a sample of the subject, wherein a frequency of TILs having the CD8+CD28−CD152− signature above a predetermined level is indicative of a positive responsiveness to cancer treatment. Other signatures reflecting responsiveness to cancer treatment are also disclosed. In addition, methods of treating cancer based on these signatures are also disclosed.

    Abstract translation: 公开了一种确定对癌症治疗的反应性的方法。 该方法包括分析受试者样本中具有CD8 + CD28-CD152特征的肿瘤浸润性淋巴细胞（TIL）的频率，其中具有高于预定水平的CD8 + CD28-CD152特征的TIL频率指示 对癌症治疗的积极反应。 还公开了反映对癌症治疗反应的其他签名。 此外，还公开了基于这些标记治疗癌症的方法。

Patent Agency Ranking